Literature DB >> 31394183

Spray-dried anti-Campylobacter bacteriophage CP30A powder suitable for global distribution without cold chain infrastructure.

Nicholas B Carrigy1, Lu Liang2, Hui Wang1, Samuel Kariuki3, Tobi E Nagel4, Ian F Connerton2, Reinhard Vehring5.   

Abstract

Campylobacter jejuni is a leading cause of foodborne illness globally. In this study, a spray drying and packaging process was developed to produce a thermally-stable dry powder containing bacteriophages that retains biological activity against C. jejuni after long distance shipping at ambient temperature. Spray drying using a twin-fluid atomizer resulted in significantly less (p < 0.05) titer reduction than spray drying using a vibrating mesh nebulizer. The use of centrifugation and dilution of filtered bacteriophage lysate in the formulation step resulted in a significantly greater (p < 0.05) proportion of bacteriophages remaining active relative to use of no centrifugation and dilution. The spray-dried bacteriophage powder generated using leucine and trehalose as excipients was flowable, non-cohesive, and exhibited a high manufacturing yield. The powder retained its titer with no significant differences (p > 0.05) in biological activity after storage in suitable packaging for at least 3 weeks at room temperature and after ambient temperature shipping a total distance of approximately 19,800 km, including with a 38 °C temperature excursion. The bacteriophage powder therefore appears suitable for global distribution without the need for cold chain infrastructure.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Campylobacter jejuni; Global health; Particle engineering; Phage CP20; Phage CP30A; Shipping stability

Mesh:

Substances:

Year:  2019        PMID: 31394183     DOI: 10.1016/j.ijpharm.2019.118601

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

Review 1.  Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs.

Authors:  Hak-Kim Chan; Rachel Yoon Kyung Chang
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2021-12-30       Impact factor: 3.440

Review 2.  Phage Biocontrol of Campylobacter: A One Health Approach.

Authors:  Sophie Kittler; Severin Steffan; Elisa Peh; Madeleine Plötz
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

Review 3.  Bacteriophage Therapy for Critical and High-Priority Antibiotic-Resistant Bacteria and Phage Cocktail-Antibiotic Formulation Perspective.

Authors:  Gursneh Kaur; Ritika Agarwal; Rakesh Kumar Sharma
Journal:  Food Environ Virol       Date:  2021-06-12       Impact factor: 2.778

4.  Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate.

Authors:  Mellissa Gomez; Joseph McCollum; Hui Wang; Mani Ordoubadi; Chester Jar; Nicholas B Carrigy; David Barona; Isobel Tetreau; Michelle Archer; Alana Gerhardt; Chris Press; Christopher B Fox; Ryan M Kramer; Reinhard Vehring
Journal:  Int J Pharm       Date:  2020-12-02       Impact factor: 5.875

Review 5.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

Review 6.  Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment.

Authors:  Jiaqi Li; Huangliang Zheng; Sharon Shui Yee Leung
Journal:  Pharm Res       Date:  2022-09-19       Impact factor: 4.580

7.  Development of a Lyophilization Process for Campylobacter Bacteriophage Storage and Transport.

Authors:  Lu Liang; Nicholas B Carrigy; Samuel Kariuki; Peter Muturi; Robert Onsare; Tobi Nagel; Reinhard Vehring; Phillippa L Connerton; Ian F Connerton
Journal:  Microorganisms       Date:  2020-02-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.